Successful desensitization therapy involving fluoroquinolone for the treatment of a solitary tuberculoma: A case report and literature review

Watanabe,Hidehiro; Uruma,Tomonori; Seita,Ikuo; Chikasawa,Yushi; Kikuchi,Ryota; Itoh,Masayuki; Aoshiba,Kazutetsu; Nakamura,Hiroyuki; Oishi,Tsuyoshi

doi:10.3892/mco.2016.881

July-2016 Volume 5 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2016 Volume 5 Issue 1

Full Size Image

Case Report

Successful desensitization therapy involving fluoroquinolone for the treatment of a solitary tuberculoma: A case report and literature review

Authors:
- Hidehiro Watanabe
- Tomonori Uruma
- Ikuo Seita
- Yushi Chikasawa
- Ryota Kikuchi
- Masayuki Itoh
- Kazutetsu Aoshiba
- Hiroyuki Nakamura
- Tsuyoshi Oishi
View Affiliations / Copyright

Affiliations: Department of Infection Control and Infectious Disease, Ibaraki Medical Center, Tokyo Medical University, Inashiki, Ibaraki 300-0395, Japan, Department of Respiratory Medicine, Ibaraki Medical Center, Tokyo Medical University, Inashiki, Ibaraki 300-0395, Japan
Pages: 117-120
|
Published online on: April 28, 2016

https://doi.org/10.3892/mco.2016.881
Expand metrics +

Abstract

The patient was a 31-year-old female with no previous health problems; however, during a health checkup in 2013, a nodule (2.5 cm in diameter) was identified in the S10 area of the left lung. No clinical symptoms were apparent. Positron emission tomography/computed tomography revealed an accumulation in the same region. The patient was suspected of having lung cancer, and video‑assisted thoracoscopic surgery was performed. A histopathological examination of the resected specimen revealed epithelioid granulomas accompanied by caseous necrosis in the lesion. The culture was positive for Mycobacterium tuberculosis, which led to the final diagnosis of tuberculoma. Initially, the patient underwent anti‑M.tuberculosis treatment [isoniazid (INH) + rifampicin (RFP) + ethambutol (EB) + pyrazinamide (PZA)]. However, two weeks later, the development of epatic dysfunction necessitated suspension of the medication. Treatment was resumed following improvement of the hepatic function. However, this relapsed two weeks later, resulting in discontinuation of the treatment. The patient was negative for each of the four drugs in the drug‑induced lymphocyte stimulation test (DLST), and drug‑induced hepatotoxicity (DIH) attributable to the anti-tuberculous drugs that were administered. Therefore, desensitization therapy was initiated. EB + PZA were changed to levofloxacin (LVFX) at an initial dose of 250 mg/day (dose level increased to the maintenance dose). Subsequently, desensitization therapy with RFP and INH was applied in accordance with the Japanese Society for Tuberculosis protocol. After each drug dose level reached the maintenance dose level, the therapy was completed following administration of the drugs for the recommended duration of 6 months. There were no signs of relapse 6 months following completion of the therapy. Therefore, the patient responded well to the substitute therapy with LVFX and desensitization therapy, and the present case report provided information regarding the treatment of tuberculoma.

View Figures

View References

1.	Andreu J, Cáceres J, Pallisa E and Martinez-Rodriguez M: Radiological manifestations of pulmonary tuberculosis. Eur J Radiol. 51:139–149. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Lee HS, Oh JY, Lee JH, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS and Yim JJ: Response of pulmonary tuberculomas to anti-tuberculous treatment. Eur Respir J. 23:452–455. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Hsu KY, Lee HC, Ou CC and Luh SP: Value of video-assisted thoracoscopic surgery in the diagnosis and treatment of pulmonary tuberculoma: 53 cases analysis and review of literature. J Zhejiang Univ Sci B. 10:375–379. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Zhan P, Xie H, Xu C, Hao K, Hou Z, et al: Management strategy of solitary pulmonary nodules. J Thorac Dis. 5:824–829. 2013.PubMed/NCBI
5.	Sathekge MM, Maes A, Pottel H, Stoltz A and van de Wiele C: Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 100:598–601. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Japan, Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou03/dl/13Accessed. June 10–2015
7.	Luh SP and Liu HP: Video-assisted thoracic surgery-the past, present status and the future. J Zhejiang Univ Sci B. 7:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Totanarungroj K, Chaopotong S and Tongdee T: Distinguishing small primary lung cancer from pulmonary tuberculoma using 64-slices multidetector CT. J Med Assoc Thai. 95:574–582. 2012.PubMed/NCBI
9.	Combs DL, O'Brien RJ and Geiter LJ: USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med. 112:397–406. 1990. View Article : Google Scholar : PubMed/NCBI
10.	Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ and Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 23:192–202. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al: ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee: An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 174:935–952. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, et al: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 4:256–261. 2000.PubMed/NCBI
13.	Zuberi BF, Zuberi FF, Bader N, Alvi H and Salahuddin J: Comparison of British Thoracic Society and American Thoracic Society reintroduction guidelines for anti-tuberculous therapy induced liver injury. J Pak Med Assoc. 64:896–899. 2014.PubMed/NCBI
14.	Devarbhavi H: Antituberculous drug-induced liver injury: Current perspective. Trop Gastroenterol. 32:167–174. 2011.PubMed/NCBI
15.	Abbasi MA, Ahmed N, Suleman A, Zaman H, Tariq S, Anwar SA and Khan N: Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity. J Ayub Med Coll Abbottabad. 26:384–388. 2014.PubMed/NCBI
16.	Laisaar T, Viiklepp P and Hollo V: Long-term follow-up after thoracoscopic resection of solitary pulmonary tuberculoma. Indian J Tuberc. 61:51–56. 2014.PubMed/NCBI
17.	Yang SH, Zhan P, Mao HH, Shi XD and Wang LL: Perfusing chemotherapy by percutaneous lung puncture ‘holing’ for pulmonary tuberculoma-a ten-year single center experience. J Thorac Dis. 5:466–471. 2013.PubMed/NCBI
18.	Kobashi Y, Abe T, Shigeto E, Yano S, Kuraoka T and Oka M: Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med. 49:2297–2301. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT and Lee JH: Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 30:167–172. 2015. View Article : Google Scholar : PubMed/NCBI
20.	Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC and Luh KT: Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 48:1526–1533. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful desensitization therapy involving fluoroquinolone for the treatment of a solitary tuberculoma: A case report and literature review

This article is mentioned in:

Abstract

Figure 1

Related Articles